Already have an ACS ID? Log in
Renew your membership, and continue to enjoy these benefits.
Already an ACS Member? Log in here
Choose the membership that is right for you. Discount will be applied automatically at checkout.
Enjoy these benefits no matter which membership you pick.
Most Popular in Pharmaceuticals
Novo Nordisk has licensed antibody technology from Durham, N.C.-based Argos Therapeutics for the development of drugs to treat systemic immune disorders. The deal could be worth up to $69 million for Argos, which will receive up-front and milestone payments, as well as royalties on any drugs developed through its technology. Using its dendritic cell-based technology platform, Argos has found monoclonal antibodies that target INF-alpha, which is vital to the onset and maintenance of lupus. Separately, Novo has signed an agreement to study the use of Nastech Pharmaceutical's molecular biology-based drug delivery technology with several of its compounds.
This article has been sent to the following recipient: